| Identification | Back Directory | [Name]
1H-Indene-2-carboxylicacid,1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-5-propoxy-,(1S,2R,3S)- | [CAS]
167256-08-8 | [Synonyms]
SB217242
SB-217242
SB 217242
Enrasentan
1H-Indene-2-carboxylicacid,1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-5-propoxy-,(1S,2R,3S)- | [Molecular Formula]
C29H30O8 | [MDL Number]
MFCD00947631 | [MOL File]
167256-08-8.mol | [Molecular Weight]
506.54 |
| Hazard Information | Back Directory | [Definition]
ChEBI: Enrasentan is a member of the class of indanes that is 2,3-dihydro-1H-indene which is substituted by a 1,3-benzodioxol-5-yl group, carboxy group, 2-(2-hydroxyethoxy)-4-methoxyphenyl group and a propoxy group at positions 1S, 2R, 3S and 5, respectively. It is an orally active mixed endothelin A/B receptor antagonist with a 100-fold greater affinity for the endothelin A receptor. The drug was being developed by GSK for the treatment of congestive heart failure and pulmonary hypertension (clinical trials discontinued). It has a role as an endothelin receptor antagonist and an antihypertensive agent. It is a monocarboxylic acid, a member of benzodioxoles, an aromatic ether, a member of indanes, a monomethoxybenzene and a primary alcohol. |
|
|